-
EZ Cap™ Firefly Luciferase mRNA Workflow Guide
2026-08-11
Build sensitive, transient reporter assays for mRNA delivery, translation benchmarking, gene regulation, and in vivo imaging with a Cap1- and poly(A)-optimized luciferase transcript. Practical controls, formulation choices, and troubleshooting guidance help separate delivery failure from biological or detection-related variability.
-
Cefodizime in AMR E. coli Research Workflows
2026-08-10
Use Cefodizime as a mechanistic bacterial cell wall synthesis inhibitor in susceptibility testing, resistance surveillance, and host–pathogen assay design. This workflow connects the compound’s PBP activity with the urban-rodent Escherichia coli findings from Hanoi while emphasizing controls, formulation, and interpretation limits.
-
Intravesical p21 mRNA-LNP Therapy in Bladder Cancer
2026-08-09
The reference study develops chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. Its findings connect restored nuclear p21 expression with cell-cycle inhibition, DNA-damage signaling, apoptosis, and reduced orthotopic tumor growth, while also highlighting the translational advantages and remaining questions of local mRNA delivery.
-
pH-Sensitive Nanoparticles Reverse BCSC Drug Resistance
2026-08-08
This study developed SchB/AP nanoparticles to co-deliver all-trans retinoic acid and schisandrin B while exploiting acidic intracellular conditions for enhanced release. In vitro results indicate that the platform can improve activity against breast cancer stem cells by promoting lysosomal escape, reducing P-glycoprotein-mediated efflux, and disrupting the energy supply that supports multidrug resistance.
-
Sodium Citrate for Reproducible SERS Arrays
2026-08-07
Sodium citrate can improve control of colloidal gold preparation and provide a practical buffer and chelation variable in polymer pen lithography workflows. This guide connects citrate handling with 3D gold nanocluster assembly, quantitative SERS quality control, and troubleshooting for reproducible analytical substrates.
-
Evaluating Fumagillin’s Antiparasitic Efficacy in Soft Tunic
2026-08-07
This study systematically assesses the efficacy of Fumagillin and other compounds against Azumiobodo hoyamushi, the protozoan responsible for soft tunic syndrome in Halocynthia roretzi. The findings clarify Fumagillin’s moderate antiparasitic activity, framing its potential and limitations for aquaculture disease management.
-
3-Deazaneplanocin (DZNep): Epigenetic Modulation for Transla
2026-08-06
Explore how 3-Deazaneplanocin (DZNep) is reshaping translational cancer research through mechanistic epigenetic modulation, rigorous protocol optimization, and strategic guidance for targeting tumor-initiating cells. This article integrates mechanistic insight, protocol pragmatism, and forward-looking perspective—bridging molecular innovation with translational opportunity.
-
Trilaurin (Glycerol Tridodecanoate) in Oral Peptide Drug Del
2026-08-06
Trilaurin sets itself apart as a multifunctional lipid excipient, enabling advanced solid lipid microparticle platforms and biocatalytic workflows that enhance the oral delivery of sensitive peptide and protein drugs. Its unique release-modulating and protective properties position it as a cornerstone for both pharmaceutical formulation and biochemical synthesis innovation.
-
3X (DYKDDDDK) Peptide: Precision Tools for Metabolic Protein
2026-08-05
Explore the 3X (DYKDDDDK) Peptide as a cornerstone for high-sensitivity affinity purification and detection of metabolic proteins. This in-depth article reveals unique assay considerations and emerging applications in cancer metabolism, offering expert insights for advanced research.
-
Rosiglitazone (Brl-49653): Unraveling PPARγ’s Role in Adipos
2026-08-05
Explore how Rosiglitazone (Brl-49653) uniquely advances PPARγ-driven white adipose tissue browning and metabolic research. This in-depth analysis highlights novel mechanistic insights and practical assay implications, distinct from standard protocol guides.
-
Optimizing mRNA Delivery: Next-Level Insights with EZ Cap™ F
2026-08-04
Discover how EZ Cap™ Firefly Luciferase mRNA elevates mRNA delivery and translation efficiency assays. This article uniquely synthesizes new lipid nanoparticle research with practical protocol guidance, offering advanced strategies for robust bioluminescent reporting.
-
Asymmetric Synthesis of Axially Chiral Antimitotic Biaryls
2026-08-04
This study reports the first catalytic asymmetric Suzuki cross-coupling applied to the synthesis of an axially chiral biaryl analogue of (-)-rhazinilam, a compound with potent antimitotic properties. The innovative use of binaphthyl chiral ligands enabled the enantioselective construction of complex natural product analogues, offering new strategies for accessing bioactive chiral molecules relevant to cytoskeletal and metabolic studies.
-
Fast-Onset Antidepressant Action via SERT-nNOS Disruption in
2026-08-03
Chen et al. identify esflurbiprofen as a rapid-acting antidepressant by targeting the SERT-nNOS interaction in the dorsal raphe nucleus, bypassing the classical delays of SSRI therapy. This work advances screening strategies for modulators of serotonergic signaling, with implications for translational neuropharmacology.
-
Reliable Reporter Assays with EZ Cap™ Firefly Luciferase mRN
2026-08-03
This article explores scenario-driven challenges in cell-based reporter assays and demonstrates how EZ Cap™ Firefly Luciferase mRNA (SKU R1018) addresses common lab pain points around sensitivity, reproducibility, and workflow optimization. Practical recommendations, quantitative context, and protocol guidance are synthesized for scientists seeking robust mRNA delivery and bioluminescent readouts.
-
Alpha-Ketoglutarate: A Metabolic Lever for Translational Onc
2026-08-02
Recent breakthroughs reveal how alpha-ketoglutarate accumulation, driven by PDHA1 succinylation, orchestrates immune evasion in cholangiocarcinoma. This thought-leadership article dissects the mechanistic rationale, strategic opportunities, and protocol considerations for translational researchers leveraging α-KGA in metabolic reprogramming, enzyme system studies, and tumor microenvironment modulation. It contextualizes APExBIO’s alpha-ketoglutarate within high-impact workflows and presents a forward-looking perspective on overcoming chemotherapy resistance through metabolic intervention.